Jetstar to Charge for Overhead Cabin Bags From February 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
YAVNE, Israel, March 08, 2018 -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will present a corporate overview at the Cowen & Company 38th Annual Health Care Conference and the Oppenheimer & Co 28th Annual Healthcare Conference.
| Cowen & Company 38th Annual Health Care Conference | |
| Date: | Wednesday, March 14 |
| Time: | 9:20 am Eastern Time |
| Location: | Boston Marriott Copley Place, Vineyard Ballroom, 4th Floor |
| Oppenheimer & Co. 28th Annual Healthcare Conference | |
| Date: | Tuesday, March 20 |
| Time: | 2:45 pm Eastern Time |
| Location: | Westin New York Grand Central, Track 61 |
About MediWound Ltd.
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid®, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel and Argentina. NexoBrid® represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues.
MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®. In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com.
Contacts:
Sharon Malka
Chief Financial and Operations Officer
MediWound
[email protected]
Bob Yedid
Managing Director
LifeSci Advisors, LLC
[email protected]
